# PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

> **NCT06245889** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 30 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Pembrolizumab
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Olaparib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06245889
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2029-06
- **Final completion:** 2030-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06245889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06245889, "PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06245889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*